S&P 500 Gains and Losses Today: Eli Lilly Stock Soars as Weight-Loss Pill Shows Promise; Beverage Makers Face Pressure
1. Eli Lilly stock surged 5.9% on positive trial results for orforglipron. 2. Orforglipron met endpoints for weight loss in Type 2 diabetes patients. 3. LLY plans to submit regulatory request for its oral GLP-1 treatment. 4. Overall market gained 0.4%, with LLY being the top performer. 5. Investor sentiment was cautious amid political concerns yet lifted by LLY news.